A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma

被引：1
|
作者：
Luscan, Gerald [1 ]
Paccagnella, Luisa [2 ]
Patel, Krish [3 ]
机构：
[1] Pfizer Int Org, Global Prod Dev, Paris, France
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Swedish Canc Inst, Seattle, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
    Strati, Paolo
    Agajanian, Richy
    Lossos, Izidore S.
    Coleman, Morton
    Kridel, Robert
    Wood, Andrew
    Lesley, Robin
    Wun, Chuan-Chuan
    Stephens, Deborah M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
  • [32] A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Czuczman, Myron S.
    Trneny, Marek
    Davies, Andrew
    Rule, Simon
    Linton, Kim M.
    Wagner-Johnston, Nina
    Gascoyne, Randy D.
    Slack, Graham W.
    Brousset, Pierre
    Eberhard, David A.
    Hernandez-Ilizaliturri, Francisco J.
    Salles, Gilles
    Witzig, Thomas E.
    Zinzani, Pier Luigi
    Wright, George W.
    Staudt, Louis M.
    Yang, Yandan
    Williams, P. Mickey
    Lih, Chih-Jian
    Russo, Jacqueline
    Thakurta, Anjan
    Hagner, Patrick
    Fustier, Pierre
    Song, Dale
    Lewis, Ian D.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4127 - 4137
  • [33] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    LEUKEMIA RESEARCH, 2019, 83
  • [34] Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study
    Koh, Youngil
    Byun, Ja Min
    Hong, Junshik
    Lim, Sung-nam
    Kim, Seok Jin
    Kong, Jee Hyun
    Lee, Gyeong-Won
    Kim, Hyo Jung
    Kim, Da Jung
    Lee, Jeong-Ok
    Park, Young-Hun
    Yoon, Dok Hyun
    Yoo, Kwai Han
    Kang, Hye Jin
    Yang, Deok-Hwan
    Kwak, Jae-Yong
    Kwon, Jung Hye
    Kang, Ka Won
    Baek, Dong Won
    Yoon, Sung-Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
    Abramson, Jeremy S.
    Ku, Matthew
    Hertzberg, Mark
    Huang, Hui-Qiang
    Fox, Christopher P.
    Zhang, Huilai
    Yoon, Dok Hyun
    Kim, Won-Seog
    Abdulhaq, Haifaa
    Townsend, William
    Herbaux, Charles
    Zaucha, Jan M.
    Zhang, Qing-Yuan
    Chang, Hung
    Liu, Yanyan
    Cheah, Chan Yoon
    Ghesquieres, Herve
    Simko, Stephen
    Orellana-Noia, Victor
    Ta, Richard
    Relf, James
    Dixon, Mark
    Kallemeijn, Martine
    Mulvihill, Estefania
    Huang, Huang
    Lundberg, Linda
    Gregory, Gareth P.
    LANCET, 2024, 404 (10466): : 1940 - 1954
  • [36] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
    Bennani, N. Nora
    Nowakowski, Grzegorz
    Rimsza, Lisa M.
    Adjei, Alex A.
    Doyle, Laurence
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [37] Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
    Hess, Brian T.
    Solh, Melhem M.
    Gandhi, Mitul
    Wang, Ying
    Qin, Yajuan
    Yu, Eric
    Zinzani, Pier Luigi
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
    Ayers, Emily C.
    Depaus, Julien
    Offner, Fritz
    Hu, Marie
    Okada, Craig
    Urban, Andrzej
    Niewiarowski, Andrew
    Rave, Erica
    Laughlin, Mary
    Alderuccio, Juan Pablo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S474 - S474
  • [39] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
    Deng, Lijuan
    Li, Zhiming
    Zhang, Huilai
    Huang, Haiwen
    Hu, Jianda
    Liu, Lihong
    Liu, Ting
    Jin, Jie
    Zhu, Zunmin
    Li, Wenyu
    Huang, Zhenqian
    Huang, Wenrong
    Zhou, Keshu
    Yang, Haiyan
    Zhang, Mingzhi
    Ding, Kaiyang
    Zhou, Hui
    Hu, Yu
    Shuang, Yuerong
    Cao, Junning
    Gao, Sujun
    Li, Dengju
    Sun, Zimin
    Zhang, Qingyuan
    Yi, Shuhua
    Ji, Chunyan
    Zhang, Liansheng
    Hou, Cheng
    Du, Yue
    Wang, Weige
    Zhao, Renbin
    Song, Yuqin
    Zhu, Jun
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
  • [40] Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study
    Oberstein, Paul Eliezer
    Moreno, Victor
    Raghav, Kanwal Pratap Singh
    Hong, Yong Sang
    Han, Sae-Won
    Su, Yu-Li
    Yuan, Ying
    Pietrantonio, Filippo
    Van Cutsem, Eric
    Eng, Cathy
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Bhattacharya, Rianka
    Maul, Raymond Scott
    Iwasawa, Ryota
    Schnepp, Robert W.
    Knoblauch, Roland Elmar
    Thayu, Meena
    Ho, Gwo Fuang
    Kim, Han Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 135 - 135
12345